QIAGEN N.V. (QGEN) recently launched QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.The latest development will strongly boost the QIAGEN Digital Insights (“QDI”) bioinformatics business of the Genomics / NGS product group.News in DetailQIAGEN Biomedica ...

Venlo, the Netherlands, and Redwood City, California, Feb. 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven knowledge base designed to propel drug discovery in the pharma and biotech industries. This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery. QIAGEN Biomedical KB-AI is built on ...

QIAGEN N.V. (QGEN) recently announced two significant achievements in sustainability, recognized by My Green Lab — a non-profit organization dedicated to advancing sustainability in scientific research. The company earned the prestigious ACT (Accountability, Consistency, and Transparency) Environmental Impact Factor Label for the new QIAwave products and achieved My Green Lab Platinum certification for its Sample technologies R&D lab in Germany.These recognitions underscore QIAGEN’s commitment to sustainabi ...

Forward looking and intended use statements Q4: $503 million CER(1) vs outlook of ≥ $500 m CER 2023 adjusted diluted EPS Adj. EPS: ≥ $2.10 CER • QuantiFERON: +24% CER FY sales, annual sales milestone of >$400m Strong profitability profile supports capital deployment • Closely monitoring macro-economic and customer demand trends Q4 2023: +8% CER growth from non-COVID product groups Growth rates vs. Q4 2022. | Refer to appendix for product group growth at actual rates. | Tables may contain rounding difference ...

Qiagen N.V. (NYSE:QGEN) Q4 2023 Earnings Conference Call February 7, 2024 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - Chief Executive Officer Roland Sackers - Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Odysseas Manesiotis - Berenberg Casey Woodring - JPMorgan Aisyah Noor - Morgan Stanley Douglas Schenkel - Wolfe Research Falko Friedrichs - Deutsche Bank Matthew Sykes - Goldman Sachs Operator Good day. I'm Melin ...

QIAGEN N.V.’s (QGEN) fourth-quarter 2023 adjusted earnings per share (EPS) were 55 cents (same at a constant exchange rate or CER), up 3.8% from the prior-year period. However, the figure missed the Zacks Consensus Estimate by 1.8%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 42 cents, u ...

Qiagen (QGEN) reported $509.16 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 2.3%. EPS of $0.55 for the same period compares to $0.55 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $504.16 million, representing a surprise of +0.99%. The company delivered an EPS surprise of -1.79%, with the consensus EPS estimate being $0.56.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

QIAGEN N.V. (QGEN) recently announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, “One Health Microbiome Center”, to support faculty and students.The latest development will significantly boost the company’s Life Sciences business ar ...

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, w ...

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. The repayment from existing cash reserves is expected to lead to an approximately 3% reduction in the number of issued shares (based on current share price). The terms of the syntheti ...